Guggenheim initiates coverage of Kazia Therapeutics with Buy rating and $35 price target
Guggenheim Research began coverage of Kazia Therapeutics, assigning a Buy rating and a $35 price target. The firm highlighted the lead asset paxalisib and cited early trial data showing five responses out of six patients and a 100% disease‑control rate in metastatic triple‑negative breast cancer. The note estimates a potential upside of about 344% from the current share price of $7.88. The coverage comes as Kazia recently completed a $40 million public offering priced at $15.50 per ADS.
Why it matters
Guggenheim’s target implies a 344% upside, suggesting significant upside potential for investors if the clinical program progresses as expected (the company expects). The analyst’s valuation may drive buying interest and affect the stock’s volatility.
Key facts
- 1Guggenheim set a price target of $35.00 per share. investing.com
- 2The target represents a potential upside of 344% from the current price of $7.88. investing.com
- 3Kazia’s beta is 2.27. investing.com
- 4The company’s market capitalization is $108 million. investing.com
- 5Enterprise value is approximately $50 million. investing.com
- 6Kazia announced a $40 million public offering, pricing each ADS at $15.50. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.